3 Managing disease activity during treatment with natalizumab in relapsing-remitting multiple sclerosis
risk phenotype for MOGAD, although one was diagnosed with a likely parainfectious myelitis and another as transverse myelitis associated with Sjogren's syndrome.Conclusion A CSF-restricted MOG-IgG profile is rare, with over half of these patients having an alternate non-MOGAD diagnosis confirmed.We strongly recommend the use of serum as the biospecimen of preference in testing for MOG IgG.We additionally urge caution in the interpretation of CSFrestricted MOG-IgG in unselected patients who do not have clinical, radiological or ancillary investigations consistent with MOGAD.
Authors
- Sifat Sharmin (ORCID: https://orcid.org/0000-0001-7294-9723)
- Jeannette Lechner‐Scott (ORCID: https://orcid.org/0000-0002-3850-447X)
- Nevin John (ORCID: https://orcid.org/0000-0002-9834-4498)
- Tomáš Kalinčík (ORCID: https://orcid.org/0000-0003-3778-1376)
- Katherine Buzzard (ORCID: https://orcid.org/0000-0003-4039-9303)
- Helmut Butzkueven (ORCID: https://orcid.org/0000-0003-3940-8727)
- Anneke van der Walt (ORCID: https://orcid.org/0000-0002-4278-7003)
- Izanne Roos (ORCID: https://orcid.org/0000-0003-0371-3666)
- Nathaniel Lizak (ORCID: https://orcid.org/0009-0009-3213-8390)
- Suzanne Hodgkinson (ORCID: https://orcid.org/0000-0002-9029-6663)
- Mark Slee (ORCID: https://orcid.org/0000-0003-4323-2453)
- Olga Skibina (ORCID: https://orcid.org/0009-0000-1542-5659)
Institutions
- The Royal Melbourne Hospital (AU)
- Box Hill Hospital (AU)
- The University of Melbourne (AU)
- Flinders University (AU)
- The Alfred Hospital (AU)
- Hunter Medical Research Institute (AU)
- Ingham Institute (AU)
- Monash University (AU)
Publication Details
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1136/bmjno-2024-anzan.3
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00